




Searching News Database: monoclonal antibody
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 31 Jan 2025
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
HSMN NewsFeed - 18 Mar 2024
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
HSMN NewsFeed - 11 Dec 2023
Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer
Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer
HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
HSMN NewsFeed - 4 Jan 2023
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
HSMN NewsFeed - 12 Aug 2022
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
HSMN NewsFeed - 21 Jun 2022
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
HSMN NewsFeed - 20 Apr 2022
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
HSMN NewsFeed - 3 Dec 2021
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
HSMN NewsFeed - 2 Sep 2021
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
HSMN NewsFeed - 7 Oct 2020
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
HSMN NewsFeed - 4 Sep 2020
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
HSMN NewsFeed - 4 Sep 2020
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
HSMN NewsFeed - 24 Aug 2020
Leap Therapeutics Expands Leadership Team with Addition of Two Industry Veterans
Leap Therapeutics Expands Leadership Team with Addition of Two Industry Veterans
HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
HSMN NewsFeed - 10 Aug 2020
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
HSMN NewsFeed - 1 Jun 2020
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
HSMN NewsFeed - 19 May 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
HSMN NewsFeed - 7 May 2020
FogPharma Appoints Tony Gibney as Chief Financial Officer and Chief Business Officer
FogPharma Appoints Tony Gibney as Chief Financial Officer and Chief Business Officer
HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
HSMN NewsFeed - 12 Mar 2020
ImmunoPrecise Announces the Launch of PolyTope mAb Therapy(TM) to Tackle Coronavirus Pandemic
ImmunoPrecise Announces the Launch of PolyTope mAb Therapy(TM) to Tackle Coronavirus Pandemic
HSMN NewsFeed - 14 Feb 2020
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
HSMN NewsFeed - 28 Jan 2020
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
HSMN NewsFeed - 24 Oct 2019
Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
HSMN NewsFeed - 19 Feb 2019
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
HSMN NewsFeed - 10 Jan 2019
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
HSMN NewsFeed - 28 Nov 2018
MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
HSMN NewsFeed - 16 Aug 2018
CBT Pharmaceuticals Announces New Leadership Structure to Drive Global Expansion
CBT Pharmaceuticals Announces New Leadership Structure to Drive Global Expansion
HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
HSMN NewsFeed - 23 May 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
HSMN NewsFeed - 3 Apr 2018
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
HSMN NewsFeed - 14 Mar 2018
Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing
Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing
HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
HSMN NewsFeed - 22 Jan 2018
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
HSMN NewsFeed - 4 Dec 2017
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
HSMN NewsFeed - 12 Sep 2017
Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
HSMN NewsFeed - 17 Jul 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 24 May 2017
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
HSMN NewsFeed - 22 Dec 2016
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
HSMN NewsFeed - 22 Jul 2016
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
HSMN NewsFeed - 22 Jul 2016
ContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer
ContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer
HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
HSMN NewsFeed - 1 Jul 2016
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
HSMN NewsFeed - 11 May 2016
Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
HSMN NewsFeed - 9 May 2016
Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs
Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs
HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
HSMN NewsFeed - 23 Mar 2016
Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing
Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing
HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
HSMN NewsFeed - 26 Feb 2016
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 9 Feb 2016
Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS(TM) System for Male Infertility
Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS(TM) System for Male Infertility
HSMN NewsFeed - 25 Jan 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 12 Jan 2016
Aytu BioScience Obtains CE Marking for Company's MiOXSYS(TM) System for Male Infertility
Aytu BioScience Obtains CE Marking for Company's MiOXSYS(TM) System for Male Infertility
HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 1 Oct 2015
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
HSMN NewsFeed - 10 Sep 2015
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
HSMN NewsFeed - 27 Aug 2015
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
HSMN NewsFeed - 20 Aug 2015
Alder BioPharmaceuticals Appoints Paul B. Cleveland to Board of Directors
Alder BioPharmaceuticals Appoints Paul B. Cleveland to Board of Directors
HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
HSMN NewsFeed - 13 May 2015
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development
HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
HSMN NewsFeed - 23 Apr 2015
Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing
Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing
HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
HSMN NewsFeed - 16 Apr 2014
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
HSMN NewsFeed - 3 Mar 2014
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
HSMN NewsFeed - 12 Feb 2014
Osiris Therapeutics Promotes Frank Czworka to Vice President and General Manager of Wound Care
Osiris Therapeutics Promotes Frank Czworka to Vice President and General Manager of Wound Care
HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
HSMN NewsFeed - 2 Dec 2013
Visterra Closes $8.1 Million Financing and Expands Executive Team to Accelerate Company Growth
Visterra Closes $8.1 Million Financing and Expands Executive Team to Accelerate Company Growth
HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
HSMN NewsFeed - 9 Sep 2013
Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
HSMN NewsFeed - 12 Aug 2013
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
HSMN NewsFeed - 15 Jul 2013
Visterra Appoints Brian Pereira, M.D., as President and Chief Executive Officer
Visterra Appoints Brian Pereira, M.D., as President and Chief Executive Officer
HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
HSMN NewsFeed - 4 Feb 2013
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
HSMN NewsFeed - 18 Dec 2012
CytoDyn Elects Two New Directors and Appoints New Chief Financial Officer
CytoDyn Elects Two New Directors and Appoints New Chief Financial Officer
HSMN NewsFeed - 9 Nov 2012
Visterra Secures Financing From Gates Foundation and Omega to Close $26M Series A Financing
Visterra Secures Financing From Gates Foundation and Omega to Close $26M Series A Financing
HSMN NewsFeed - 5 Jun 2012
Former Pfizer Worldwide Business Development Director Joins Australian Drug Development Company Agenix
Former Pfizer Worldwide Business Development Director Joins Australian Drug Development Company Agenix
HSMN NewsFeed - 3 May 2012
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
HSMN NewsFeed - 10 Apr 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
HSMN NewsFeed - 6 Mar 2012
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
HSMN NewsFeed - 9 Nov 2011
PharmAthene Appoints Linda L. Chang Senior Vice President, Chief Financial Officer
PharmAthene Appoints Linda L. Chang Senior Vice President, Chief Financial Officer
HSMN NewsFeed - 13 Sep 2011
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
HSMN NewsFeed - 28 Jul 2011
Ramona M. Lloyd, Ph.D., RAC, Joins Omthera Pharmaceuticals as Vice President Regulatory Affairs
Ramona M. Lloyd, Ph.D., RAC, Joins Omthera Pharmaceuticals as Vice President Regulatory Affairs
HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
HSMN NewsFeed - 17 Jun 2011
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
HSMN NewsFeed - 15 Apr 2011
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
HSMN NewsFeed - 7 Jan 2011
MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
HSMN NewsFeed - 13 Dec 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
HSMN NewsFeed - 14 Oct 2010
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
HSMN NewsFeed - 9 Aug 2010
Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A
Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A
HSMN NewsFeed - 17 Jun 2010
Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
HSMN NewsFeed - 7 Jun 2010
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
HSMN NewsFeed - 24 May 2010
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
HSMN NewsFeed - 24 May 2010
Seattle Genetics Names Vice President, Sales and Announces Management Promotion
Seattle Genetics Names Vice President, Sales and Announces Management Promotion
Additional items found! 500

Members Archive contains
500 additional stories matching:
monoclonal antibody
(Password required)
monoclonal antibody
(Password required)